FDA Grants Approval for Everolimus ANDA219464
The FDA has granted approval for the ANDA219464 application for Everolimus submitted by I3 PHARMS.
Published: July 8, 2026
Updated: July 8, 2026
Author: Humanexa Intelligence
Therapeutic area: Oncology / mTOR Inhibitor
Asset: Everolimus
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
Everolimus
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Everolimus ANDA219464 signifies a new entrant in the oncology market, which may disrupt existing competitive dynamics. Portfolio teams must evaluate the implications for market share and pricing strategies of current mTOR inhibitors.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor market entry timelines and any subsequent pricing strategies from I3 PHARMS.
Related companies & assets
Assets
Sources & Humanexa intelligence
Source links
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.